Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-9899-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-LMO2 Monoclonal Antibody (1A9-3B11), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: This 1A9-3B11 monoclonal antibody reacts with human LMO2, a member of the LIM-only family of zinc finger proteins. LMO2 possesses two LIM domains for homodimerization and an N-terminal transactivation domain. This 24-kDa transcription factor can be found as part of a transcriptional complex composed of TAL1, E47, GATA-1, and LDB1 proteins. LMO2 is expressed in myeloid cells, germinal center B cells, vascular endothelium, and a variety of cancers, including diffuse large B cell lymphomas (DLBCL), T cell acute lymphoblastic lymphomas, and vascular neoplasms. Expression of LMO2 in germinal center B cells has been shown to be regulated by microRNAs, specifically hsa-miR-223. Although the function of LMO2 remains unclear in germinal center B cells, this factor is involved in hematopoiesis and oncogenesis. In addition, expression of this molecule has been demonstrated to be prognostic marker for survival in DLBCL patients. Applications Reported: This 1A9-3B11 antibody has been reported for use in immunohistochemical staining. Applications Tested: This 1A9-3B11 antibody has been tested by immunohistochemistry on human tonsil tissue and western blot on the Raji cell line. This can be used at 0.5-10 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 1A9-3B11
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.
The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins.
Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Jan 20;26(3):447-54
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Jan 20;26(3):447-54
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.
Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS, Hamilton Dutoit S, Lossos IS, Levy R
Blood 2007 Feb 15;109(4):1636-42
Blood 2007 Feb 15;109(4):1636-42
The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins.
Wadman IA, Osada H, Grütz GG, Agulnick AD, Westphal H, Forster A, Rabbitts TH
The EMBO journal 1997 Jun 2;16(11):3145-57
The EMBO journal 1997 Jun 2;16(11):3145-57
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry of human tonsil tissue at a 1:1000 dilution of Anti-Human LMO2 Purified followed by Anti-Mouse IgG Biotin (Product # 13-4013-85) and avidin HRP (Product # 18-4100-51). Low (left) and high (right) magnifications are shown.
